|
1
|
National Cancer Institute. SEER Cancer
Statistics Review, 1975–2006. http://seer.cancer.gov/csr/1975_2006/.
Accessed: April 12, 2012
|
|
2
|
Buzaid AC, Colome M, Bedikian A, Eton O,
Legha SS, Papadopoulos N, Plager C, Ross M, Lee JE, Mansfield P, et
al: Phase II study of neoadjuvant concurrent biochemotherapy in
melanoma patients with local-regional metastases. Melanoma Res.
8:549–556. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stein ME, Bernstein Z, Drumea K, Zalik M,
Shklar Z, Steiner M and Haim N: Sustained complete remission after
chemobiohormonal therapy for metastatic melanoma. Am J Clin Oncol.
22:62–64. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gibbs P, Anderson C, Pearlman N, LaClaire
S, Becker M, Gatlin K, O’Driscoll M, Stephens J and Gonzalez R: A
phase II study of neoadjuvant biochemotherapy for stage III
melanoma. Cancer. 94:470–476. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sasson HN, Poo WJ, Bakas MH and Ariyan S:
Prolonged survival in patients with advanced melanoma treated with
neoadjuvant chemotherapy followed by resection. Ann Plast Surg.
37:286–292. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bar J, Yerushalmi R, Shapira-Frummer R,
Kutchuk I, Sulkes A, Gutman H, Catane R and Schachter J: Concurrent
chemobio- therapy with cisplatin, dacarbazine, decrescendo
interleukin-2 and interferon α2b in patients with metastatic
melanoma. Oncol Rep. 20:1533–1538. 2008.PubMed/NCBI
|
|
7
|
O’Day S and Boasberg P: Management of
metastatic melanoma 2005. Surg Oncol Clin N Am. 15:419–437.
2006.
|
|
8
|
Hwu WJ, Panageas KS, Menell JH, Lamb LA,
Aird S, Krown SE, Williams LJ, Chapman PB, Livingston PO, Wolchok
JD and Houghton AN: Phase II study of temozolomide plus pegylated
interferon-alpha-2b for metastatic melanoma. Cancer. 106:2445–2451.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lewis KD, Robinson WA, McCarter M,
Pearlman N, O’Day SJ, Anderson C, Amatruda TT, Baron A, Zeng C,
Becker M, et al: Phase II multicenter study of neoadjuvant
biochemotherapy for patients with stage III malignant melanoma. J
Clin Oncol. 24:3157–3163. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moschos SJ, Edington HD, Land SR, Rao UN,
Jukic D, Shipe-Spotloe J and Kirkwood JM: Neoadjuvant treatment of
regional stage IIIB melanoma with high-dose interferon alfa-2b
induces objective tumor regression in association with modulation
of tumor infiltrating host cellular immune responses. J Clin Oncol.
24:3164–3171. 2006. View Article : Google Scholar
|
|
11
|
Hauschild A, Agarwala SS, Trefzer U, Hogg
D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J,
et al: Results of a phase III, randomized, placebo-controlled study
of sorafenib in combination with carboplatin and paclitaxel as
second-line treatment in patients with unresectable stage III or
stage IV melanoma. J Clin Oncol. 27:2823–2830. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sarnaik AA, Zager JS and Sondak VK:
Multidisciplinary management of special melanoma situations:
oligometastatic disease and bulky nodal sites. Curr Oncol Rep.
9:417–427. 2007. View Article : Google Scholar
|
|
13
|
Stephens FO: Induction chemotherapy: to
downgrade aggressive cancers to improve curability by surgery
and/or radiotherapy. Eur J Surg Oncol. 27:672–688. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gutman H, Hess KR, Kokotsakis JA, Ross MI,
Guinee VF and Balch CM: Surgery for abdominal metastases of
cutaneous melanoma. World J Surg. 25:750–758. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mosca PJ, Teicher E, Nair SP and Pockaj
BA: Can surgeons improve survival in stage IV melanoma? J Surg
Oncol. 97:462–468. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schachter J, Rakowsky E, Sulkes A and
Adler A: A sequential four-drug chemotherapy and biotherapy with
interferon alpha and GM-CSF - an innovative protocol for the
treatment of metastatic melanoma. Cancer Biother Radiopharm.
13:155–164. 1998. View Article : Google Scholar : PubMed/NCBI
|
